UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C.  20549

                                Form 10-Q

(Mark One)

  x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
 ---                SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended March 31, 2002

                                   OR

      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
 ---                SECURITIES EXCHANGE ACT OF 1934

   For the transition period from       to
                                  ------   ------
                     Commission File No. 000-20139

                               Diacrin, Inc.
          (Exact name of registrant as specified in its charter)


	      Delaware	                        22-3016912
(State or other jurisdiction of              (I.R.S. Employer
incorporation or organization)               Identification No.)


                  Building 96  13th Street, Charlestown Navy Yard,
                               Charlestown, MA  02129
             (Address of principal executive offices, including zip code)

                                     (617) 242-9100
                  (Registrant's telephone number, including area code)

	Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.

			YES   X               NO
                      -----                ----

	Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.

	As of April 30, 2002, 17,937,204 shares of the registrant's Common
Stock were outstanding.

                                      -1-
<PAGE>

                                  Diacrin, Inc.
                                      Index


                                                                Page
PART I. -	FINANCIAL INFORMATION

Item 1.		Financial Statements

	      Balance Sheets as of
	      December 31, 2001 and March 31, 2002...................3

	      Statements of Operations for each of the three month
	      periods ended March 31, 2001 and 2002..................4

	      Statements of Cash Flows for each of the three month
            periods ended March 31, 2001 and 2002..................5

	      Notes to Financial Statements..........................6

Item 2.	Management's Discussion and Analysis of Financial
		Condition and Results of Operations....................8

Item 3.	Quantitative and Qualitative Disclosure About
	      Market Risk............................................19

PART II. -	OTHER INFORMATION

Item 2.	Changes in Securities and Use of Proceeds..............20

Item 6.	Exhibits and Reports on Form 8-K.......................20

SIGNATURES.........................................................21

             Cautionary Note Regarding Forward-Looking Statements

     This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 concerning our business, operations and financial condition, including
statements with respect to planned timetables for the initiation and completion
of various clinical trials and the expected sources of porcine cells used in our
products. All statements, other than statements of historical facts included in
this Quarterly Report on Form 10-Q regarding our strategy, future operations,
timetables for product testing, financial position, costs, prospects, plans and
objectives of management are forward-looking statements. When used in this
Quarterly Report on Form 10-Q, the words "expect," "anticipate," "intend,"
"plan," "believe," "seek," "estimate" and similar expressions are intended to
identify forward looking statements, although not all forward-looking
statements contain these identifying words. Because these forward-looking
statements involve risks and uncertainties, actual results could differ
materially from those expressed or implied by these forward-looking
statements for a number of important reasons, including those discussed under
"Certain Factors That May Affect Future Results," "Management's Discussion
and Analysis of Financial Condition and Results of Operations" and elsewhere
in this Quarterly Report on Form 10-Q.

     You should read these statements carefully because they discuss our
expectations about our future performance, contain projections of our future
operating results or our future financial condition, or state other "forward-
looking" information. You should be aware that the occurrence of any of the
events described in these risk factors and elsewhere in this Quarterly Report
on Form 10-Q could substantially harm our business, results of operations and
financial condition and that upon the occurrence of any of these events, the
trading price of our common stock could decline.

     We cannot guarantee any future results, levels of activity, performance or
achievements.  The forward-looking statements contained in this Quarterly
Report on Form 10-Q represent our expectations as of the date this Quarterly
Report on Form 10-Q was first filed with the Securities and Exchange
Commission and should not be relied upon as representing our expectation as
of any other date.  Subsequent events and developments will cause our
expectations to change.  However, while we may elect to update these
forward-looking statements, we specifically disclaim any obligation to do so
even if our expectations change.

                                       -2-

<PAGE>


                                    Diacrin, Inc.
                                   Balance Sheets
                                     (Unaudited)

<TABLE>
<CAPTION>
							                 December 31,		        March 31,
							  	              2001		           2002
<S>                                                    <C>                  <C>
ASSETS
Current assets:
	Cash and cash equivalents                          $     8,534,426	$      6,986,246
	Short-term investments	                                33,410,736      	40,818,068
	Interest receivable and other current assets	           668,020	         843,194
                                                          --------------       ---------------
		Total current assets	                          42,613,182	      48,647,508
                                                          --------------       ---------------
Property and equipment, at cost:
	Laboratory and manufacturing equipment	               1,660,963             1,667,368
      Furniture and office equipment	                       324,913               327,382
	Leasehold improvements	                                    77,529                77,529
                                                           -------------        --------------
                                                               2,063,405             2,072,279
	Less- Accumulated depreciation and amortization	         1,861,110             1,910,019
                                                           -------------        --------------
		                                                     202,295               162,260
                                                           -------------        --------------

Long-term investments                                          7,782,035                   -
Investment in joint venture                                       83,984                41,712
                                                           -------------        --------------
	Total other assets                                       7,866,019                41,712
                                                           -------------        --------------

Total assets                                             $    50,681,496       $    48,851,480
                                                           =============         =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Current portion of long-term debt                   $      119,167        $       86,667
	Accounts payable                                           117,663                78,773
	Accrued expenses                                         1,269,278             1,027,106
	Deferred revenue from joint venture                         29,238                35,788
                                                           -------------        --------------
		Total current liabilities                          1,535,346             1,228,334
                                                           -------------        --------------
Stockholders' equity:
	Preferred stock, $.01 par value, authorized--
		5,000,000 shares; none issued and outstanding            -                     -
	Common stock, $.01 par value; authorized-- 30,000,000
		shares; issued and outstanding--17,937,204
		shares at December 31, 2001 and
		March 31, 2002                                       179,372              179,372
	Additional paid-in capital                             101,401,822          101,401,822
	Accumulated deficit                                    (52,435,044)	    (53,958,048)
                                                           -------------        --------------
			Total stockholders' equity                  49,146,150           47,623,146
                                                           -------------        --------------

Total liabilities and stockholders' equity              $     50,681,496      $    48,851,480
						                        ============        ==============

             The accompanying notes are an integral part of these financial statements

</TABLE>

                                           -3-

<PAGE>

                                       Diacrin, Inc.
                                 Statements of Operations
                                        (Unaudited)

<TABLE>
<CAPTION>
					                                      Three Months
	     					                               Ended March, 31
            						           2001                         2002
<S>                                                   <C>                          <C>
REVENUES:
   Research and development                            $    383,062                 $      32,588
   Investment income                                        908,858                       456,613
		                                            -----------                  ------------
	Total revenues                                      1,291,920                       489,201
	                                                  -----------                  ------------

OPERATING EXPENSES:
    Research and development                              1,450,067                     1,622,336
    General and administrative                              425,502                       357,195
    Interest expense                                          5,183                         1,264
	                                                  -----------                   -----------
	Total operating expenses                            1,880,752                     1,980,795
	                                                  -----------                   -----------

EQUITY IN OPERATIONS OF JOINT VENTURE                      (222,430)                      (31,410)

                                                         ----------                   -----------
NET LOSS                                               $   (811,262)              $    (1,523,004)
                                                         ==========                   ===========
BASIC AND DILUTED
     NET LOSS PER COMMON SHARE                            $    (.05)                   $     (.08)
                                                         ==========                   ===========
SHARES USED IN COMPUTING BASIC AND
     DILUTED NET LOSS PER COMMON SHARE                   17,914,704                    17,937,204
                                                         ==========                    ==========


                    The accompanying notes are an integral part of these financial statements


</TABLE>

                                                            -4-

<PAGE>

                                                       Diacrin, Inc.
                                                  Statements of Cash Flows
                                                        (Unaudited)

<TABLE>
<CAPTION>
									                   Three Months
									                  Ended March 31,
							 	                    2001                2002
<S>                                                            <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
	Net loss	                                              $ (811,262)        $ (1,523,004)
	Adjustments to reconcile net loss to net
		cash used in operating activities-
			Depreciation and amortization                     53,928               48,909
			Equity in operations of joint venture            222,430               31,410
	Changes in assets and liabilities-
		Interest receivable and other current assets          (188,449)            (175,174)
		Accounts payable                                        (8,551)             (38,890)
		Accrued expenses                                      (157,462)            (242,172)
		Deferred revenue                                      (167,073)               6,549
                                                                 ---------           ----------

			Net cash used in operating activities         (1,056,439)          (1,892,372)
                                                                 ---------            ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
	Increase in short-term investments                        (1,380,831)          (7,407,332)
	Purchases of property and equipment, net                      (3,850)              (8,874)
	Decrease in long-term investments                          3,508,068            7,782,035
	Investment in joint venture                                 (357,987)                 -
	Return of capital for services provided
       on behalf of joint venture                                  127,687               10,863
                                                                 ---------             --------

			Net cash provided by investing activities      1,893,087              376,692
                                                                 ---------             --------
CASH FLOWS FROM FINANCING ACTIVITIES:
	Principal payments on long-term debt                         (32,500)             (32,500)
                                                                 ---------             --------

			Net cash used in financing activities            (32,500)             (32,500)
                                                                 ---------             --------
NET INCREASE (DECREASE) IN CASH
	AND CASH EQUIVALENTS                                         804,148           (1,548,180)

CASH AND CASH EQUIVALENTS, beginning of period                  11,143,116            8,534,426
                                                                ----------            ---------

CASH AND CASH EQUIVALENTS, end of period                     $  11,947,264         $  6,986,246
                                                                ==========            =========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
	Cash paid for interest during the period                   $   5,183            $   1,264
                                                                ==========            =========

                 The accompanying notes are an integral part of these financial statements

</TABLE>

                                          -5-

<PAGE>

                                      Diacrin, Inc.
                               Notes to Financial Statements
                                       (Unaudited)

1.	Operations and Basis of Presentation

	Diacrin, Inc. (the "Company") was incorporated on October 10, 1989
and is developing transplantable cells for the treatment of human diseases
which are characterized by cell dysfunction or cell death and for which current
therapies are either inadequate or nonexistent.

	The financial statements included herein have been prepared by the
Company, without audit, pursuant to the rules and regulations of the Securities
and Exchange Commission and include, in the opinion of management, all
adjustments, consisting of normal, recurring adjustments, necessary for a fair
presentation of interim period results.  Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations.  The Company believes, however, that
its disclosures are adequate to make the information presented not misleading.
The results for the interim periods presented are not necessarily indicative of
results to be expected for the full fiscal year or any future periods.  These
financial statements should be read in conjunction with the audited financial
statements and notes thereto included in the Company's latest Annual Report
on Form 10-K filed with the Securities and Exchange Commission.

2.	Summary of Significant Accounting Policies

	(a)	Joint Venture Agreement

	In September 1996, the Company and Genzyme Corporation
("Genzyme") formed a joint venture (the "Joint Venture") to develop and
commercialize two product candidates.  The Joint Venture is funded by
Genzyme and the Company in accordance with the terms of the joint venture
agreement.  Collaborative revenue under the joint venture agreement with
Genzyme is recognized as revenue to the extent that the Company's research
and development costs are funded by Genzyme through the Joint Venture.
The Company receives non-refundable advances from the Joint Venture.
Deferred revenue represents amounts received prior to recognition of revenue.
Research and development costs are expensed as incurred.

	The detail of the Company's investment in the joint venture for the
first quarter is as follows:




                                                      2002
                                                     ------
Balance, beginning of quarter                    $     83,984
                                                 ------------
Contributions to joint venture                             -
Return of capital                                     (10,862)
Funding of operations of joint venture                (31,410)
                                                 ------------
Balance, end of quarter                          $     41,712
                                                 ============

                                     -6-

<PAGE>



                                Diacrin, Inc.
                        Notes to Financial Statements
                                 (Unaudited)

	Contributions to the joint venture represent cash contributions. The
return of capital represents cash payments made to the Company by the joint
venture for research and development costs that are funded by the Company.
Funding of operations of the joint venture represents costs incurred by
Genzyme on behalf of the joint venture, which are funded by the Company.

	A summary of the revenue and expenses from the joint venture are as
follows:

						  Three months ended March 31,

                                            2001              2002
                                           ------            ------

Revenue recognized                        $383,062           $32,588
Research and development expense          $510,749           $43,451
Equity in operations of joint venture     $222,430           $31,410


	(b)	Net Loss per Common Share

	 In accordance with Statement of Financial Accounting Standards
("SFAS") No. 128, Earnings per Share, basic and diluted net loss per share is
calculated by dividing the net loss by the weighted average number of
common shares outstanding for all periods presented. Diluted weighted
average shares outstanding for all periods presented exclude the potential
common shares from stock options of 1,260,247 and 1,513,872 at March 31,
2001 and 2002, respectively, because to include such shares would be
antidilutive.

3.	Cash Equivalents and Investments

	The Company's cash equivalents and investments are classified as
held-to-maturity and are carried at amortized cost, which approximates fair
market value.  Cash equivalents, short-term investments and long-term
investments have maturities of less than three months, less than one year and
greater than one year, respectively.  Cash equivalents, short-term investments
and long-term investments at December 31, 2001 and March 31, 2002
consisted of the following:

<TABLE>
<CAPTION>

                                                                              December 31, 2001    March 31, 2002
<S>                                                                           <C>                 <C>
Cash and cash equivalents-
    Cash                                                                          $      1,003        $    1,003
    Money market mutual fund                                                         8,533,423         6,985,243
                                                                                  ------------       -----------
                                                                                 $   8,534,426     $   6,986,246
                                                                                  ============       ===========
Short-term investments-
    Corporate notes (remaining avg. mat. of 4 mos. at Mar. 31, 2002)            $   26,651,221     $  30,732,251
    U.S. gov't oblig. & agencies (remaining avg. mat. of 6 mos. at Mar. 31, 2002)    6,510,826        10,085,817
    Commercial paper                                                                   248,689             -
                                                                                  ------------        ----------
                                                                                 $  33,410,736     $  40,818,068
                                                                                  ============        ==========
Long-term investments-
    Corporate notes                                                              $   4,198,142             -
    U.S. gov't obligations                                                           3,583,893             -
                                                                                  ------------        ----------
                                                                                $    7,782,035             -
                                                                                  ============        ==========
</TABLE>

                                              -7-

<PAGE>

Item 2. 	Management's Discussion and Analysis of Financial
Condition and Results of Operations

Overview
	Since our inception, we have principally focused our efforts and
resources on research and development of cell transplantation technology for
treating human diseases that are characterized by cell dysfunction or cell death
and for which current therapies are either inadequate or nonexistent.  Our
primary source of working capital to fund those activities has been proceeds
from the sale of equity and debt securities. In addition, since October 1, 1996,
we have received funding from our joint venture with Genzyme in support of
the joint venture's product development programs.  We have not received any
revenues from the sale of products to date and do not expect to generate
product revenues for the next several years.  We have experienced fluctuating
operating losses since inception and expect that the additional activities
required to develop and commercialize our products will result in increasing
operating losses for the next several years.  At March 31, 2002, we had an
accumulated deficit of $54.0 million.

	In 1996, we formed a joint venture with Genzyme to develop and
commercialize two product candidates.  We are currently responsible for
funding 25% of the development and commercialization costs of the joint
venture and will share all costs in excess of $50 million equally with
Genzyme.  As of March 31, 2002, approximately $33.0 million had been
contributed to the joint venture by Genzyme and approximately $7.6 million
had been contributed by us.

Critical Accounting Policies

     Our significant accounting policies are discussed in Note 2 of our
audited financial statements which are included in our latest Annual Report on
Form 10-K filed with the Securities and Exchange Commission. We believe
our most critical accounting policies are those that dictate how we recognize
revenue and expense related to the joint venture's activity. We record as
research and development expense all costs related to the joint venture's
product candidates incurred by us on behalf of the joint venture. We then
recognize research and development revenue equal to the amount of
reimbursement received by us from the joint venture out of funds contributed
by Genzyme. We do not recognize research and development revenue for
amounts we receive from the joint venture out of funds contributed by us. As
Genzyme incurs costs on behalf of the joint venture that we are obligated to
fund, we recognize an expense in our statement of operations captioned
"Equity in operations of joint venture."

Results of Operations

Three Months Ended March 31, 2002 Versus Three Months Ended March 31, 2001

	Research and development revenues of approximately $33,000 for the
three months ended March 31, 2002 and $383,000 for the three months ended
March 31, 2001 were derived exclusively from the Joint Venture.  The
decrease in revenues was primarily a result of a decrease in clinical
production activity related to the Joint Venture's product candidates.

	Investment income was $457,000 and $909,000 for the three months
ended March 31, 2002 and 2001, respectively.  The decrease in investment
income was due to lower cash balances available for investment in the current
year period and a lower return on investment due to the decline in interest
rates.


                                     -8-

<PAGE>

     Research and development expenses were $1.6 million and $1.5
million for the three months ended March 31, 2002 and 2001, respectively.
The increase in research and development expenses is due to an increase in
clinical and production costs related to our human muscle cells for
cardiac disease and porcine spinal cord cells for spinal cord injury product
candidates.

     General and administrative expenses were $357,000 and $426,000 for
the three months ended March 31, 2002 and 2001, respectively. The decrease
in general and administrative expenses was primarily due to a decrease in
professional fees.

     For the three months ended March 31, 2002 and 2001, the Company
recorded an expense of $31,000 and $222,000, respectively, related to its
equity in operations of the joint venture.  This expense was due to funds
contributed by the Company to the Joint Venture that were used to fund
expenses incurred by Genzyme on behalf of the Joint Venture. The decreased
charge in the current year period was primarily due to a decrease in clinical
activity performed by Genzyme on behalf of the joint venture.

     The Company incurred a net loss of approximately $1.5 million for the
three months ended March 31, 2002 versus approximately $811,000 for the
three months ended March 31, 2001.

Liquidity and Capital Resources

	We have financed our activities primarily with the net proceeds from
the sale of equity and debt securities aggregating $102 million and with the
interest earned thereon. In addition, we have recorded approximately  $15.3
million in revenue from our joint venture since it commenced on October 1,
1996.  At March 31, 2002, we had cash and cash equivalents and short-term
investments aggregating approximately $47.8 million.

	In November 1997, we borrowed $650,000 at the prime rate plus 0.5%
(5.25% at March 31, 2002) under an unsecured five-year term loan with a
bank to finance our biomedical animal facility acquired during 1997.  At
March 31, 2002 we had $86,667 outstanding under the borrowing. We had no
material commitments for capital expenditures as of March 31, 2002. In
October 2000, we exercised the first of two options we have to extend the
lease of a facility an additional five years. During the extension period,
which began in October 2001, we will pay annual rent of approximately $908,000.

	We believe that our existing funds will be sufficient to fund our
operating expenses and capital requirements as currently planned for the
foreseeable future.  However, our cash requirements may vary materially from
those now planned because of results of research and development, the scope
and results of preclinical and clinical testing, any termination of the joint
venture, relationships with future strategic partners, changes in the focus and
direction of our research and development programs, competitive and
technological advances, the FDA's regulatory process, the market acceptance
of any approved products and other factors.

	We expect to incur substantial additional costs, including costs related
to ongoing research and development activities, preclinical studies, clinical
trials, expanding our cell production capabilities and the expansion of our
laboratory and administrative activities. Therefore, in order to achieve
commercialization of our potential products, we may need substantial
additional funds. We cannot assure you that we will be able to obtain the
additional funding that we may require on acceptable terms, if at all.

Certain Factors That May Affect Future Results

     The following important factors, among others, could cause actual results
to differ materially from those contained in forward-looking statements made
in this Quarterly Report on Form 10-Q or presented elsewhere by management
from time to time. The forward-looking statements contained in this Quarterly
Report on Form 10-Q represent our expectations as of May 8, 2002, the date
our Quarterly Report on Form 10-Q was filed with the SEC. Subsequent
events will cause our expectations to change.  However, while we may elect to
update these forward-looking statements, we specifically disclaim any
obligation to do so.  See "Cautionary Note Regarding Forward-Looking
Statements."

                                     -9-

<PAGE>

Risks Related to Our Business, Industry and Strategy

     We have not successfully commercialized any products to date and, if
we do not successfully commercialize any products, we will not be
profitable

     Neither we nor any other company has received regulatory approval to
market the types of products we are developing. The products that we are
developing will require additional research and development, clinical trials
and regulatory approval prior to any commercial sale. Our product candidates
are currently in early phase clinical trials or in the preclinical stage of
development. Our products may not be effective in treating any of our targeted
disorders or may prove to have undesirable or unintended side effects,
toxicities or other characteristics that may prevent or limit their commercial
use.

     We currently have no products for sale and do not expect to have any
products available for sale for several years. If we are not successful in
developing and commercializing any products, we will never become
profitable.

     The evaluation of the unblinded data from our Phase 2 clinical trial of
NeuroCell-PD may not support further development

     In March 2001, we unblinded our Phase 2 clinical trial of NeuroCell-PD
and announced a preliminary analysis of the results.  We did not see a
statistically significant difference between the treated patients and the
patients in the control group and, therefore, did not meet the primary endpoint
in the trial. While we are still evaluating the data from this clinical trial,
it is possible that further clinical development of NeuroCell-PD by the joint
venture will not be supported by Genzyme, or that we may choose to discontinue
development or modify the clinical trial protocols, which could result in the
termination of or significant delay in the progress of the NeuroCell-PD
development program or the termination of the joint venture.

     Our cell transplantation technology is complex and novel and there
are uncertainties as to its effectiveness

     We have concentrated our efforts and therapeutic product research on cell
transplantation technology, and our future success depends on the successful
development of this technology. Our principal approach is based upon
xenotransplantation, or the transplantation of cells, tissues or organs from
one species to another. Our product candidates generally involve the
transplantation of porcine (pig) neural cells into humans. Xenotransplantation
is an emerging technology with limited clinical experience. Neither the FDA
nor any foreign regulatory body has approved any xenotransplantation-based
therapeutic product for humans.

     Our technological approaches may not enable us to successfully develop
and commercialize any products. If our approaches are not successful, we may
be required to change the scope and direction of our product development
activities. In that case, we may not be able to identify and implement
successfully an alternative product development strategy.

     Xenotransplantation involves risks which have resulted in additional
FDA oversight and which in the future may result in additional
regulation

     Xenotransplantation poses a risk that viruses or other animal pathogens
may be unintentionally transmitted to a human patient. The FDA requires us
to perform tests to determine whether infectious agents, including porcine
endogenous retroviruses, referred to as PERV, are present in patients who
have received porcine cells. While PERV has not been shown to cause any
disease in pigs, it is not known what effect, if any, PERV may have on
humans. We have performed tests on patients who have received our porcine
cells. No PERV has been detected to date, but we cannot assure you that we
will not detect PERV or another infectious agent in the future.


                                   -10-

<PAGE>

    The FDA requires lifelong monitoring of porcine cell transplant recipients.
If PERV or any other virus or infectious agent is detected in tests or samples,
the FDA may require us to halt our clinical trials and perform additional tests
to assess the risk to patients of infection. This could result in additional
costs to us and delays in the trials of our porcine cell products. Furthermore,
even if patients who have received our porcine cells remain PERV-free, we could
be adversely affected if PERV is detected in patients who receive porcine cells
provided by others.

     In January 2001, the FDA issued definitive regulatory guidelines for
xenotransplantation titled "PHS Guideline on Infectious Disease Issues in
Xenotransplantation." We cannot assure you that we will be able to comply
with these guidelines.

     We face substantial competition, which may result in others
discovering, developing or commercializing products before or more
successfully than we do

     The products we are developing compete with existing and new products
being developed by pharmaceutical, biopharmaceutical and biotechnology
companies, as well as universities and other research institutions. Many of our
competitors are substantially larger than we are and have substantially greater
capital resources, research and development staffs and facilities than we have.
Efforts by other biotechnology or pharmaceutical companies could render our
products uneconomical or result in therapies for the disorders we are targeting
that are superior to any therapy we develop. Furthermore, many of our
competitors are more experienced in product development and
commercialization, obtaining regulatory approvals and product manufacturing.
As a result, they may develop competing products more rapidly and at a lower
cost. These competitors may discover, develop and commercialize products
which render non-competitive or obsolete the products that we are seeking to
develop and commercialize.

     If the market is not receptive to our products upon introduction, our
products may not achieve commercial success

     The commercial success of any of our products will depend upon their
acceptance by patients, the medical community and third-party payors.
Among the factors that we believe will materially affect acceptance of our
products are:

     - the timing of receipt of marketing approvals and the countries in which
       those approvals are obtained;

     - the safety and efficacy of our products;

     - the need for surgical administration of our products;

     - problems encountered in the field of xenotransplantation;

     - the success of physician education programs;

     - the cost of our products which may be higher than conventional
       therapeutic products because our products involve surgical
       transplantation of living cells; and

     - the availability of government and third-party payor reimbursement of
       our products.

                                     -11-

<PAGE>

Risks Relating to Clinical and Regulatory Matters

     If our clinical trials are not successful for any reason, we will not be
able to develop and commercialize any related products

     In order to obtain regulatory approvals for the commercial sale of our
product candidates, we will be required to complete extensive clinical trials
in humans to demonstrate the safety and efficacy of the products. We have
limited experience in conducting clinical trials.

     The submission of an investigational new drug application, or IND, may
not result in FDA authorization to commence clinical trials. If clinical trials
begin, we may not complete testing successfully within any specific time
period, if at all, with respect to any of our product candidates. Furthermore,
we or the FDA may suspend clinical trials at any time on various grounds,
including a finding that the patients are being exposed to unacceptable health
risks. Clinical trials, if completed, may not show any potential product to be
safe or effective. Thus, the FDA and other regulatory authorities may not
approve any of our product candidates for any disease indication.

     The rate of completion of clinical trials depends in part upon the rate of
enrollment of patients. Patient enrollment is a function of many factors,
including the size of the patient population, the proximity of patients to
clinical sites, the eligibility criteria for the study, the existence of
competitive clinical trials and the availability of alternative treatments. In
particular, the patient population for some of our potential products is small.
Delays in planned patient enrollment may result in increased costs and program
delays.

     We rely on third-party clinical investigators to conduct our clinical
trials. As a result, we may encounter delays outside of our control.

     We may not be able to reinitiate a clinical trial that has been
suspended by the FDA

     Clinical trials are subject to ongoing review by the FDA. The FDA has the
authority to suspend a clinical trial for various reasons, as they did in April
2000 with respect to our clinical trial using porcine neural cells to treat
stroke patients. Because our products are novel and complex, getting the FDA to
lift a suspension could result in significant program delays and additional
costs to us. It is possible that we may not be able to obtain permission from
the FDA to continue a clinical trial that has been suspended.  Cost increases
and ongoing delays as a result of an FDA suspension could result in our
decision to postpone pursuing certain product candidates.

     The regulatory approval process is costly and lengthy and we may not
be able to successfully obtain all required regulatory approvals

     We must obtain regulatory approval for each of our product candidates
before we can market or sell it. We may not receive regulatory approvals to
conduct clinical trials of our products or to manufacture or market our
products. In addition, regulatory agencies may not grant approvals on a timely
basis or may revoke previously granted approvals. Any delay in obtaining, or
failure to obtain, approvals could adversely affect the marketing of our
products and our ability to generate product revenue.

     The process of obtaining FDA and other required regulatory approvals is
lengthy and expensive. The time required for FDA and other clearances or
approvals is uncertain and typically takes a number of years, depending on the
complexity and novelty of the product. We have only limited experience in
filing and prosecuting applications necessary to gain regulatory approvals.

                                    -12-

<PAGE>

     Our analysis of data obtained from preclinical and clinical activities is
subject to confirmation and interpretation by regulatory authorities which
could delay, limit or prevent regulatory approval. Any regulatory approval to
market a product may be subject to limitations on the indicated uses for which
we may market the product. These limitations may limit the size of the market
for the product.

     We also are subject to numerous foreign regulatory requirements governing
the design and conduct of the clinical trials and the manufacturing and
marketing of our future products. The approval procedure varies among
countries. The time required to obtain foreign approvals often differs from
that required to obtain FDA approvals. Moreover, approval by the FDA does not
ensure approval by regulatory authorities in other countries.

     Even if we obtain marketing approval, our products will be subject to
ongoing regulatory oversight which may affect the success of our
products

     Any regulatory approvals that we receive for a product may be subject to
limitations on the indicated uses for which the product may be marketed or
contain requirements for costly post-marketing follow-up studies. After we
obtain marketing approval for any product, the manufacturer and the
manufacturing facilities for that product will be subject to continual review
and periodic inspections by the FDA and other regulatory authorities. The
subsequent discovery of previously unknown problems with the product, such
as the presence of PERV, or with the manufacturer or facility, may result in
restrictions on the product or manufacturer, including withdrawal of the
product from the market.

     If we fail to comply with applicable regulatory requirements, we may be
subject to fines, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions, and criminal prosecution.

Risks Relating to Financing Our Business

     We have incurred substantial losses, we expect to continue to incur
losses and we may never achieve profitability

     We have incurred losses in each year since our founding in 1989. At March
31, 2002, we had an accumulated deficit of $54.0 million. We expect to incur
substantial operating losses for the foreseeable future. We have no material
sources of revenue from product sales or license fees. We anticipate that it
will be a number of years, if ever, before we develop significant revenue
sources or become profitable, even if we are able to commercialize products.

     We expect to increase our spending significantly as we continue to expand
our research and development programs, expand our clinical trials, apply for
regulatory approvals and begin commercialization activities. In particular, we
may devote significant economic resources to funding our joint venture with
Genzyme and to its product development plans. Under the joint venture
agreement, we are currently required to provide 25% of the funding required
for the development and commercialization of two product candidates and in
the future will be required to provide 50% of the required funding.

     We may require additional financing, which may be difficult to obtain
and may dilute your ownership interest

     We will require substantial funds to conduct research and development,
including clinical trials of our product candidates, and to manufacture and
market any products that are approved for commercial sale. Our future capital
requirements will depend on many factors, including the following:

                                   -13-

<PAGE>

     - the analysis of the data from the Phase 2 clinical trial of NeuroCell-PD
       which could result in the termination of our joint venture with Genzyme;

     - continued progress in our research and development programs, as well as
       the magnitude of these programs;

     - the resources required to successfully complete our clinical trials;

     - the time and costs involved in obtaining regulatory approvals;

     - the cost of manufacturing and commercialization activities;

     - the cost of any additional facilities requirements;

     - the timing, receipt and amount of milestone and other payments from
       future collaborative partners;

     - the timing, receipt and amount of sales and royalties from our potential
       products in the market; and

     - the costs involved in preparing, filing, prosecuting, maintaining and
       enforcing patent claims and other patent-related costs, including
       litigation costs and the costs of obtaining any required licenses to
       technologies.

     We may seek additional funding through collaborative arrangements and
public or private financings. Additional financing may not be available to us
on acceptable terms or at all.

     If we raise additional funds by issuing equity securities further dilution
to our then existing stockholders may result. In addition, the terms of the
financing may adversely affect the holdings or the rights of our stockholders.
If we are unable to obtain funding on a timely basis, we may be required to
significantly curtail one or more of our research or development programs.

     We also could be required to seek funds through arrangements with
collaborative partners or others that may require us to relinquish rights to
certain of our technologies, product candidates, or products which we would
otherwise pursue independently.

Risks Relating to Intellectual Property

     We may not be able to obtain patent protection for our discoveries and
we may infringe patent rights of others

     The patent positions of pharmaceutical and biotechnology companies,
including us, are generally uncertain and involve complex legal, scientific and
factual issues.

     Our success depends significantly on our ability to:

     - obtain patents;

     - protect trade secrets;

     - operate without infringing upon the proprietary rights of others; and

     - prevent others from infringing on our proprietary rights.

                                   -14-

<PAGE>

     Patents may not issue from any patent applications that we own or license.
If patents do issue, the claims allowed may not be sufficiently broad to
protect our technology. In addition, issued patents that we own or license
may be challenged, invalidated or circumvented. Our patents also may not afford
us protection against competitors with similar technology. Because patent
applications in the United States may be maintained in secrecy until patents
issue, others may have filed or maintained patent applications for technology
used by us or covered by our pending patent applications without our being
aware of these applications.

     We may not hold proprietary rights to some patents related to our proposed
products. In some cases, others may own or control these patents. As a result,
we or our collaborative partners may be required to obtain licenses under
third-party patents to market some of our proposed products. If licenses are
not available to us on acceptable terms, we will not be able to market these
affected products.

     If we are not able to keep our trade secrets confidential, our
technology and information may be used by others to compete against us

     We rely significantly upon unpatented proprietary technology, information,
processes and know how. We seek to protect this information by
confidentiality agreements with our employees, consultants and other third-
party contractors as well as through other security measures. These
confidentiality agreements may be breached, and we may not have adequate
remedies for any such breach. In addition, our trade secrets may otherwise
become known or be independently developed by competitors.

     We may become involved in expensive patent litigation or other
intellectual property proceedings which could result in liability for
damages or stop our development and commercialization efforts

     There has been substantial litigation and other proceedings regarding the
complex patent and other intellectual property rights in the pharmaceutical and
biotechnology industries. We may become a party to patent litigation or other
proceedings regarding intellectual property rights.

     The types of situations in which we may become involved in patent
litigation or other intellectual property proceedings include:

     - we may initiate litigation or other proceedings against third parties to
       enforce our patent rights;

     - we may initiate litigation or other proceedings against third parties to
       seek to invalidate the patents held by these third parties or to obtain a
       judgment that our products or services do not infringe the third parties'
       patents;

     - if our competitors file patent applications that claim technology also
       claimed by us, we may participate in interference or opposition
       proceedings to determine the priority of invention; and

     - if third parties initiate litigation claiming that our processes or
       products infringe their patent or other intellectual property rights, we
       will need to defend against such claims.

     The cost to us of any patent litigation or other proceeding, even if
resolved in our favor, could be substantial. Some of our competitors may be able
to sustain the cost of such litigation or proceedings more effectively than we
can because of their substantially greater financial resources. If a patent
litigation or other intellectual property proceeding is resolved unfavorably to
us, we may be enjoined from manufacturing or selling our products and services
without a license from the other party and be held liable for significant
damages. We may not be able to obtain any required license on commercially
acceptable terms or at all.


                                 -15-

<PAGE>

     Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could have a material adverse effect on our
ability to compete in the marketplace. Patent litigation and other proceedings
may also absorb significant management time.

     If we breach any of the agreements under which we license technology
from others we could lose license rights that are important to our
business

     We are a party to technology in-licenses that are important to our
business and expect to enter into additional licenses in the future. In
particular, our immunomodulation technology and some of our product candidates
are covered by patents licensed from Massachusetts General Hospital. These
licenses impose commercialization, sublicensing, royalty, insurance and other
obligations on us. If we fail to comply with these requirements, the licensor
will have the right to terminate the license.

Risks Relating to Product Manufacturing, Marketing and Sales

     Since we have no sales and marketing experience or infrastructure, we
must rely on third parties

     We have no sales, marketing and distribution experience or infrastructure.
We plan to rely significantly on sales, marketing and distribution
arrangements with third parties for the products that we are developing. For
example, under our joint venture agreement, we have granted to Genzyme (on
behalf of the joint venture) exclusive worldwide marketing rights to two
product candidates. We may have limited or no control over the sales,
marketing and distribution activities of Genzyme, the joint venture or any
future collaborative partners. Our future revenues will be materially dependent
upon the success of the efforts of these third parties.

     If in the future we determine to perform sales, marketing and distribution
functions ourselves, we would face a number of additional risks, including:

     - we may not be able to attract and build a significant marketing or sales
       force;

     - the cost of establishing a marketing or sales force may not be
       justifiable in light of any product revenues; and

     - our direct sales and marketing efforts may not be successful.

     Delays in obtaining regulatory approval of our manufacturing facility
and disruptions in our manufacturing process may delay or disrupt our
commercialization efforts

     Before we can begin commercially manufacturing our product candidates,
we must obtain regulatory approval of our manufacturing facility and process.
Manufacturing of our product candidates must comply with cGMP, and
foreign regulatory requirements. The cGMP requirements govern quality
control and documentation policies and procedures. In complying with cGMP
and foreign regulatory requirements, we will be obligated to expend time,
money and effort on production, recordkeeping and quality control to ensure
that our product candidates meet applicable specifications and other
requirements. If we fail to comply with these requirements, we would be
subject to possible regulatory action and may be limited in the jurisdictions
in which we are permitted to sell our product candidates.

     We are the only manufacturers of our product candidates. For the next
several years, we expect that we will conduct all of our manufacturing in our
facility in Charlestown, Massachusetts. If this facility or the equipment in
this facility is significantly damaged or destroyed, we will not be able to
replace quickly or inexpensively our manufacturing capacity.

                                -16-

<PAGE>

     We have no experience manufacturing our product candidates in the
volumes that will be necessary to support large clinical trials or commercial
sales. Our present manufacturing process may not meet our initial
expectations as to scheduling, reproducibility, yield, purity, cost, potency or
quality.

     The manufacture of our products would be delayed by disruptions in
our supply of porcine tissue

     The manufacture of our products requires the continuous availability of
porcine tissue harvested from pigs tested to be free of infectious agents and
quarantined in a qualified animal facility. Our main sources of these
facilities and services are Tufts University School of Veterinary Medicine and
PharmServices, Inc., a division of Charles River Laboratories, Inc. A disease
epidemic or other catastrophe in either of these facilities could destroy all
or a portion of our pig supply, which would interrupt or significantly delay
the research, development and commercialization of our products.

Risks Related to Ongoing Operations

     If we fail to obtain an adequate level of reimbursement for our future
products by third party payors, there may be no commercially viable
markets for our products

     Our products may be more expensive than conventional treatments because
they involve the surgical transplantation of living cells. The availability of
reimbursement by governmental and other third-party payors affects the
market for any pharmaceutical product. These third-party payors continually
attempt to contain or reduce the costs of health care by challenging the prices
charged for medical products. In some foreign countries, particularly the
countries of the European Union, the pricing of prescription pharmaceuticals
is subject to governmental control. We may not be able to sell our products
profitably if reimbursement is unavailable or limited in scope or amount.

     In both the United States and some foreign jurisdictions, there have been
a number of legislative and regulatory proposals to change the health care
system. Further proposals are likely. The potential for adoption of these
proposals may affect our ability to raise capital, obtain additional
collaborative partners and market our products.

     If we obtain marketing approval for our products, we expect to experience
pricing pressure due to the trend toward managed health care, the increasing
influence of health maintenance organizations and additional legislative
proposals.

     We could be exposed to significant liability claims if we are unable to
obtain insurance at acceptable costs or otherwise to protect us against
potential product liability claims

     We may be subjected to product liability claims that are inherent in the
testing, manufacturing, marketing and sale of human health care products.
These claims could expose us to significant liabilities that could prevent or
interfere with the development or commercialization of our products. Product
liability claims could require us to spend significant time and money in
litigation or to pay significant damages. Product liability insurance is
generally expensive for biopharmaceutical companies such as ours. Although
we maintain limited product liability insurance coverage for the clinical
trials of our products, it is possible that we will not be able to obtain
further product liability insurance on acceptable terms, if at all, and that
our present insurance levels and any insurance we subsequently obtain will not
provide adequate coverage against all potential claims.


                                  -17-

<PAGE>

     Our growth could be limited if we are unable to attract and retain key
personnel and consultants

     Our success depends substantially on our ability to attract and retain
qualified scientific and technical personnel for the research and development
activities we conduct or sponsor. If we lose one or more of the members of our
senior management or other key employees or consultants, our business and
operating results could be seriously harmed.

     Our anticipated growth and expansion into areas and activities requiring
additional expertise, such as regulatory compliance, manufacturing and
marketing, will require the addition of new management personnel. The pool
of personnel with the skills that we require is limited. Competition to hire
from this limited pool is intense, and we may be unable to hire, train, retain
or motivate such additional personnel.

Risks Relating to our Common Stock

     Our officers and directors may be able to control the outcome of most
corporate actions requiring stockholder approval

     Our directors and officers and entities with which they are affiliated
control approximately 40% of our outstanding common stock. Due to this
concentration of ownership, this group may be able to prevail on all matters
requiring a stockholder vote, including:

     - the election of directors;

     - the amendment of our organizational documents; or

     - the approval of a merger, sale of assets or other major corporate
       transaction.

     Our stock price could be volatile, which could cause you to lose part or
all of your investment

     The market price of our common stock, like that of the common stock of
many other development stage biotechnology companies, may be highly
volatile. In addition, the stock market has experienced extreme price and
volume fluctuations. This volatility has significantly affected the market
prices of securities of many biotechnology and pharmaceutical companies for
reasons frequently unrelated to or disproportionate to the operating
performance of the specific companies. These broad market fluctuations may
adversely affect the market price of our common stock. Prices for our
common stock will be determined in the market place and may be influenced
by many factors, including variations in our financial results and investors'
perceptions of us, changes in recommendations by securities analysts as well
as their perceptions of general economic, industry and market conditions.

     We have antitakeover defenses that could delay or prevent an
acquisition and could adversely affect the price of our common stock

     Provisions of our certificate of incorporation, our bylaws, and Delaware
law may have the effect of deterring unsolicited takeovers or delaying or
preventing changes in control of our management, including transactions in
which our stockholders might otherwise receive a premium for their shares
over then current market prices. In addition, these provisions may limit the
ability of stockholders to approve transactions that they may deem to be in
their best interest.

     Our certificate of incorporation permits our board of directors to issue
preferred stock without shareholder approval upon such terms as the board of
directors may determine. The rights of the holders of our common stock will
be subject to, and may be adversely affected by, the rights of the holders of
any preferred stock that may be issued in the future. The issuance of preferred
stock, while providing desirable flexibility in connection with possible
acquisitions and other corporate purposes, could have the effect of making it
more difficult for a third party to acquire, or of discouraging a third party
from acquiring, a majority of our outstanding common stock. The issuance of a
substantial number of preferred shares could adversely affect the price of our
common stock.

                                    -18-

<PAGE>

Item 3.	Quantitative and Qualitative Disclosures About Market
Risk

	We own financial instruments that are sensitive to market risks as part
of our investment portfolio.  The investment portfolio is used to preserve our
capital until it is required to fund operations, including our research and
development activities.  None of these market-risk sensitive instruments are
held for trading purposes.  We do not own derivative financial instruments in
our investment portfolio.  Our investment portfolio contains instruments that
are subject to the risk of a decline in interest rates. For example, if the
annualized interest rate on our interest bearing investments were to change
1%, investment income would have hypothetically increased or decreased by
approximately $122,000 during the three months ended March 31, 2002. This
hypothetical analysis does not take into consideration the effects of the
economic conditions that would give rise to such an interest rate change or our
response to such hypothetical conditions.

	Our investment portfolio includes investment grade debt instruments.
These bonds are subject to interest rate risk, and could decline in value if
interest rates fluctuate.  Due to the short duration and conservative nature of
these instruments, we do not believe that it has a material exposure to
interest rate risk.

                                -19-

<PAGE>


PART II.     OTHER INFORMATION

Item 2.	Changes in Securities and Use of Proceeds

	(c) The Company did not sell any equity securities during the quarter
ended March 31, 2002 that were not registered under the Securities Act.

Item 6.	Exhibits and Reports on Form 8-K

(a)	Reports on Form 8-K

The Company did not file any Reports on Form 8-K during the quarter
ended March 31, 2002.

                                -20-

<PAGE>

                               SIGNATURES

	Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                 DIACRIN, INC.



May 8, 2002  				By:	     /s/  Thomas H. Fraser
                                            --------------------------
							          Thomas H. Fraser
							          President and
                                                    Chief Executive Officer


							     /s/  Kevin Kerrigan
							   --------------------------
                                                    Kevin Kerrigan
							          Controller





                               -21-